Drug-resistant tuberculosis: time for visionary political leadership

Hdl Handle:
http://hdl.handle.net/10144/295262
Title:
Drug-resistant tuberculosis: time for visionary political leadership
Authors:
Abubakar, I; Zignol, M; Falzon, D; Raviglione, M; Ditiu, L; Masham, S; Adetifa, I; Ford, N; Cox, H; Lawn, S D; Marais, B J; McHugh, T D; Mwaba, P; Bates, M; Lipman, M; Zijenah, L; Logan, S; McNerney, R; Zumla, A; Sarda, K; Nahid, P; Hoelscher, M; Pletschette, M; Memish, Z A; Kim, P; Hafner, R; Cole, S; Migliori, G B; Maeurer, M; Schito, M; Zumla, A
Journal:
Lancet Infectious Diseases
Abstract:
Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible to first-line tuberculosis drugs, and drug resistance was not a major issue. However, in 2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis pose formidable challenges to the global control of tuberculosis. We provide an overview of the global burden of drug-resistant disease; discuss the social, health service, management, and control issues that fuel and sustain the epidemic; and suggest specific recommendations for important next steps. Visionary political leadership is needed to curb the rise of MDR and XDR tuberculosis worldwide, through sustained funding and the implementation of global and regional action plans.
Affiliation:
Centre for Infectious Disease Epidemiology, Department of Infection and Population Health, University College London, London, UK; Health Protection Agency, London, UK
Publisher:
Elsevier
Issue Date:
24-Mar-2013
URI:
http://hdl.handle.net/10144/295262
DOI:
10.1016/S1473-3099(13)70030-6
PubMed ID:
23531391
Submitted date:
2013-06-20
Language:
en
ISSN:
1474-4457
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorAbubakar, Ien_GB
dc.contributor.authorZignol, Men_GB
dc.contributor.authorFalzon, Den_GB
dc.contributor.authorRaviglione, Men_GB
dc.contributor.authorDitiu, Len_GB
dc.contributor.authorMasham, Sen_GB
dc.contributor.authorAdetifa, Ien_GB
dc.contributor.authorFord, Nen_GB
dc.contributor.authorCox, Hen_GB
dc.contributor.authorLawn, S Den_GB
dc.contributor.authorMarais, B Jen_GB
dc.contributor.authorMcHugh, T Den_GB
dc.contributor.authorMwaba, Pen_GB
dc.contributor.authorBates, Men_GB
dc.contributor.authorLipman, Men_GB
dc.contributor.authorZijenah, Len_GB
dc.contributor.authorLogan, Sen_GB
dc.contributor.authorMcNerney, Ren_GB
dc.contributor.authorZumla, Aen_GB
dc.contributor.authorSarda, Ken_GB
dc.contributor.authorNahid, Pen_GB
dc.contributor.authorHoelscher, Men_GB
dc.contributor.authorPletschette, Men_GB
dc.contributor.authorMemish, Z Aen_GB
dc.contributor.authorKim, Pen_GB
dc.contributor.authorHafner, Ren_GB
dc.contributor.authorCole, Sen_GB
dc.contributor.authorMigliori, G Ben_GB
dc.contributor.authorMaeurer, Men_GB
dc.contributor.authorSchito, Men_GB
dc.contributor.authorZumla, Aen_GB
dc.date.accessioned2013-07-04T20:48:33Z-
dc.date.available2013-07-04T20:48:33Z-
dc.date.issued2013-03-24-
dc.date.submitted2013-06-20-
dc.identifier.citationDrug-resistant tuberculosis: time for visionary political leadership. 2013, 13 (6):529-39 Lancet Infect Disen_GB
dc.identifier.issn1474-4457-
dc.identifier.pmid23531391-
dc.identifier.doi10.1016/S1473-3099(13)70030-6-
dc.identifier.urihttp://hdl.handle.net/10144/295262-
dc.description.abstractTwo decades ago, WHO declared tuberculosis a global emergency, and invested in the highly cost-effective directly observed treatment short-course programme to control the epidemic. At that time, most strains of Mycobacterium tuberculosis were susceptible to first-line tuberculosis drugs, and drug resistance was not a major issue. However, in 2013, tuberculosis remains a major public health concern worldwide, with prevalence of multidrug-resistant (MDR) tuberculosis rising. WHO estimates roughly 630 000 cases of MDR tuberculosis worldwide, with great variation in the frequency of MDR tuberculosis between countries. In the past 8 years, extensively drug-resistant (XDR) tuberculosis has emerged, and has been reported in 84 countries, heralding the possibility of virtually untreatable tuberculosis. Increased population movement, the continuing HIV pandemic, and the rise in MDR tuberculosis pose formidable challenges to the global control of tuberculosis. We provide an overview of the global burden of drug-resistant disease; discuss the social, health service, management, and control issues that fuel and sustain the epidemic; and suggest specific recommendations for important next steps. Visionary political leadership is needed to curb the rise of MDR and XDR tuberculosis worldwide, through sustained funding and the implementation of global and regional action plans.en_GB
dc.language.isoenen
dc.publisherElsevieren_GB
dc.rightsPublished by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/journals/laninf[/url] for further relevant comment.en_GB
dc.subjectTuberculosisen_GB
dc.subjectHealth Policy/Access to Medicineen_GB
dc.titleDrug-resistant tuberculosis: time for visionary political leadershipen
dc.contributor.departmentCentre for Infectious Disease Epidemiology, Department of Infection and Population Health, University College London, London, UK; Health Protection Agency, London, UKen_GB
dc.identifier.journalLancet Infectious Diseasesen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.